Alternative Splicing and Leukemia Initiating Cells

• Conditions: Acute Myeloid Leukemia

• Registration Number: NCT03156933
• Lead Sponsor: Hospices Civils de Lyon

Brief Summary

Aberrant RNA splicing and mutations in spliceosome complex in acute myeloid leukaemia (AML) are frequent. It have been shown that some splicing variants had a prognostic value in AML.

AML are characterized by their propensity to relapse because of the persistence of leukaemia initiating cells (LICs).

The aim of this study is to determine the splice variants on AML initiator cells and define a splicing pattern.

Detailed Description

Not available

Study Timeline

• Status Verified: 2017-04
• Study Start: 2017-04-01
• Study First Submitted: 2017-04-04
• Study First Submitted QC: 2017-05-16
• Last Update Submitted: 2017-05-16
• Study First Posted: 2017-05-17
• Last Update Posted: 2017-05-17
• Primary Completion: 2018-03
• Study Completion: 2018-04

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

• Age ≥ 18 years-old
• Patients treated at the south lyon hospital center
• Patients with a diagnosis of acute myeloid leukemia confirmed in cytology and whose involvement of the 11q23 locus was confirmed by in situ hybridization
• Patients for whom a sample is available in the cytogenetic laboratory of the south lyon hospital center

Exclusion Criteria

None

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Polymerase chain reaction	1 month	Transcriptome analysis to determine the splicing variants on acute myeloid leukaemia initiator cells.; The analysis will focus on the gene encoding ABCA3 transporter and genes known to be mutated in patients with acute myeloid leukemia (FLT3, NPM1, c-Kit, N et K-RAS).; The duration of selection of samples is estimated to be one month.
Ribonucleic acid sequencing	1 month	Transcriptome analysis to determine the splicing variants on acute myeloid leukaemia initiator cells.; The analysis will focus on the gene encoding ABCA3 transporter and genes known to be mutated in patients with acute myeloid leukemia (FLT3, NPM1, c-Kit, N et K-RAS).; The duration of selection of samples is estimated to be one month.

Trial Locations

Locations (1)

Service d'hématologie du Centre Hospitalier Lyon Sud; 🇫🇷 Pierre-Bénite, France